Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravenous immunoglobulins in multiple sclerosis

R P Lisak1

  • 1Department of Neurology, Wayne State University School of Medicine, Detroit Medical Center, Michigan, USA.

Neurology
|December 16, 1998
PubMed
Summary

Intravenous immunoglobulin (IVIg) shows limited benefits for relapsing remitting multiple sclerosis (MS), with no effect on disability. Routine IVIg use is not recommended due to cost and insufficient evidence, especially for progressive MS forms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunologic characterization of oligodendroglia.

Neuroscience letters·2009
Same author

Predictors of well-being among significant others of persons with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2007
Same author

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.

Multiple sclerosis (Houndmills, Basingstoke, England)·2006
Same author

Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures.

Multiple sclerosis (Houndmills, Basingstoke, England)·2006
Same author

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.

Acta neurologica Scandinavica·2004
Same author

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.

Multiple sclerosis (Houndmills, Basingstoke, England)·2003

Area of Science:

  • Neurology
  • Immunology

Background:

  • Intravenous immunoglobulin (IVIg) is increasingly used for various diseases, including neurological conditions.
  • Recent studies have investigated IVIg for relapsing remitting multiple sclerosis (RRMS).

Purpose of the Study:

  • To evaluate the efficacy of IVIg in patients with RRMS based on recent randomized controlled trials.
  • To compare IVIg with existing MS therapies and assess its role in different MS types.

Main Methods:

  • Review of randomized, prospective, double-blind, placebo-controlled studies of IVIg in RRMS patients.
  • Analysis of reported outcomes including relapse rates, MRI activity, disability, and lesion burden.

Main Results:

  • IVIg demonstrated a reduction in relapse rate and some decrease in MRI activity.

Related Experiment Videos

  • No significant effect was observed on disability progression or overall MRI lesion burden.
  • Direct comparison with interferons and glatiramer acetate is limited by study design and patient numbers.

    • Conclusions:

    • Current evidence does not support the routine or first-line use of IVIg for RRMS due to high cost and limited demonstrated efficacy.
    • Larger studies are needed to clarify IVIg's role in MS treatment.
    • No evidence supports IVIg use in secondary progressive (SPMS) or primary progressive (PPMS) multiple sclerosis.